HIGHBuilt-inProduct / Revenue mix
64%
TriLink segment
“10-K Item 1: 'TriLink (64% of Revenue for the Year Ended December 31, 2025)'”
MRVI · Concentration risk · 10-K extracted
Maravai LifeSciences Holdings, (MRVI) concentration risks
Updated
The most significant concentration Maravai LifeSciences Holdings, discloses is TriLink segment at 64%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Maravai LifeSciences Holdings,’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 1 disclosed concentration
HIGH1
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Maravai LifeSciences' revenue base is heavily weighted toward a single segment: TriLink accounted for 64% of revenue for the year ended December 31, 2025, a high-size structural concentration. This means the company's overall results are closely tied to the performance of this one business line — its mix of nucleic acid production, mRNA-related manufacturing, and related products and services — rather than being balanced across a diversified set of segments that could offset weakness in any one area. As a structural exposure, this concentration reflects how the business itself is built rather than dependence on any single customer, supplier, or geography that could be lost; the risk is more about the durability of demand within TriLink's end markets than about a single counterparty event. Because no other concentration claims are disclosed in the reviewed sources, this segment concentration is the dominant lens for evaluating the stock: swings in TriLink's revenue — whether from mRNA-related demand, biopharma customer spending, or competitive dynamics within nucleic acid production — will flow through to the majority of Maravai's consolidated results, making segment-level trends the key variable to watch.
For the engine’s reasoning on MRVI’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| MRVI● | Maravai LifeSciences Holdings, | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.